ResearcherMayo ClinicActive in the last 2 years
Somashekar Gopala Krishna
Matched on ORCID iD 0000-0001-5748-7890; OpenAlex author ID A5005449102; NIH RePORTER profile ID 12040086. Sources: ClinicalTrials.gov.
Their work
- Papers
- 13 (first author 2, last author 3)
- Trials
- 1 (principal investigator on 1)
- Grants
- 1
- Labs led
- 2
- Collaborators
- 74
2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 trial · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper, 1 grant
Papers 13
- Disclosing a pancreatic cancer diagnosis in an era of immediate electronic result release: a national survey of endosonographers. Co-author DOI 10.1016/j.gie.2025.11.028↗
- Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
- Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
- Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies. Co-author DOI 10.21037/jgo-2025-305↗
- Early detection of concomitant pancreatic cancer during intraductal papillary mucinous neoplasms surveillance First author DOI 10.21037/gs-24-158↗
- The Role of Genetic, Metabolic, Inflammatory, and Immunologic Mediators in the Progression of Intraductal Papillary Mucinous Neoplasms to Pancreatic Adenocarci… Last author DOI 10.3390/cancers15061722↗
- Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
- Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
- Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.09.009↗
- Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. First author DOI 10.1097/mpa.0000000000000898↗
- The Burden of Systemic Adiposity on Pancreatic Disease: Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and Pancreatic Cancer. Last author PMID 29491829↗
- The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. Last author DOI 10.1016/j.gtc.2016.07.010↗
- Differentiation of pancreatic ductal adenocarcinoma from other neoplastic solid pancreatic lesions: a tertiary oncology center experience. Co-author DOI 10.1016/j.gie.2014.08.023↗
Trials 1
Grants 1
Closest collaborators
The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zobeida Cruz‐Monserrate · 6 shared papers, 2016–2023 · strength 0.63
- Paper The Role of Genetic, Metabolic, Inflammatory, and Immunologic Mediators in the Progression of Intraductal Papillary Muc… DOI 10.3390/cancers15061722↗
- Paper Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. DOI 10.1016/j.pan.2019.09.009↗
- Paper The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. DOI 10.1016/j.gtc.2016.07.010↗
- Jordan M. Cloyd · 3 shared papers, 2022–2025 · strength 0.54
- Paper Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Underg… DOI 10.1097/xcs.0000000000001277↗
- Paper Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2024.5191↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Timothy Michael Pawlik · 4 shared papers, 2017–2025 · strength 0.51
- Paper Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Underg… DOI 10.1097/xcs.0000000000001277↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Paper Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. DOI 10.1016/j.pan.2018.11.002↗
- Joanna H. Jiang · 1 shared paper, 2024 · strength 0.46
- Darwin Lewis Conwell · 5 shared papers, 2016–2019 · strength 0.41
- Paper Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. DOI 10.1016/j.pan.2019.09.009↗
- Paper The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. DOI 10.1016/j.gtc.2016.07.010↗
- Paper The Burden of Systemic Adiposity on Pancreatic Disease: Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and P… PMID 29491829↗
- Eric David Miller · 2 shared papers, 2022–2025 · strength 0.38
- Paper Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Underg… DOI 10.1097/xcs.0000000000001277↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Aslam M. Ejaz · 2 shared papers, 2022–2025 · strength 0.38
- Paper Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Underg… DOI 10.1097/xcs.0000000000001277↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Mary E. Dillhoff · 3 shared papers, 2017–2025 · strength 0.37
- Paper Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Underg… DOI 10.1097/xcs.0000000000001277↗
- Paper Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. DOI 10.1016/j.pan.2018.11.002↗
- Paper Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. DOI 10.1097/mpa.0000000000000898↗
- Samuel E. Tanner · 1 shared paper, 2026 · strength 0.29
- Jorge D. Machicado · 1 shared paper, 2026 · strength 0.29
- Daryl Ramai · 1 shared paper, 2026 · strength 0.29
- Tomas R. Davee · 1 shared paper, 2026 · strength 0.29
- Atsushi Yamaguchi · 1 shared paper, 2025 · strength 0.27
- Richard J. Bold · 1 shared paper, 2025 · strength 0.27
- Li Zhang · 1 shared paper, 2025 · strength 0.27
- Fada Luo · 1 shared paper, 2025 · strength 0.27
- Syed Ameen Ahmad · 1 shared paper, 2025 · strength 0.24
- Patrick W. Underwood · 1 shared paper, 2025 · strength 0.24
- Ashish Manne · 1 shared paper, 2025 · strength 0.24
- Phil A. Hart · 3 shared papers, 2017–2019 · strength 0.23
- Paper Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. DOI 10.1016/j.pan.2019.09.009↗
- Paper Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. DOI 10.1016/j.pan.2018.11.002↗
- Paper Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. DOI 10.1097/mpa.0000000000000898↗
- Kylie Shockley · 1 shared paper, 2023 · strength 0.22
- Wei Chen · 1 shared paper, 2023 · strength 0.22
- Anne M. Noonan · 2 shared papers, 2019–2022 · strength 0.22
- Manoop S. Bhutani · 2 shared papers, 2015–2025 · strength 0.20
- Davendra P. S. Sohal · 1 shared paper, 2025 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.